Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0E0WX
|
|||
Former ID |
DNC001683
|
|||
Drug Name |
ISIS 28472
|
|||
Drug Type |
Antisense drug
|
|||
Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
Company |
Isis Pharmaceuticals
|
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Smad7 messenger RNA (Smad7 mRNA) | Target Info | . | [1] |
KEGG Pathway | Endocytosis | |||
TGF-beta signaling pathway | ||||
Hippo signaling pathway | ||||
NetPath Pathway | TGF_beta_Receptor Signaling Pathway | |||
Panther Pathway | TGF-beta signaling pathway | |||
Pathway Interaction Database | Regulation of nuclear SMAD2/3 signaling | |||
Signaling events mediated by HDAC Class I | ||||
IFN-gamma pathway | ||||
BMP receptor signaling | ||||
ALK1 signaling events | ||||
TGF-beta receptor signaling | ||||
Reactome | SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription | |||
WikiPathways | TGF Beta Signaling Pathway | |||
TGF beta Signaling Pathway | ||||
Apoptosis-related network due to altered Notch3 in ovarian cancer | ||||
Signaling by BMP | ||||
Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | ||||
Signaling by TGF-beta Receptor Complex | ||||
Integrated Breast Cancer Pathway |
References | Top | |||
---|---|---|---|---|
REF 1 | US patent application no. 6,159,697, Antisense modulation of Smad7 expression. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.